Ticagrelor - A new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Medical Science Monitor

Volumn 15, Issue 12, 2009, Pages

  Kowalczyk, Mariusz ^a   Banach, Maciej ^a   Mikhailidis, Dimitri P ^b   Hannam, Simon ^c   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute coronary syndrome; Clopidpgrel; P2Y12 receptor; Thienopyridines; Ticagrelor

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICAGRELOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MORTALITY; NONHUMAN; SIDE EFFECT; STROKE; THROMBOCYTE AGGREGATION INHIBITION;

ACUTE CORONARY SYNDROME; ADENOSINE; ADENOSINE MONOPHOSPHATE; BIOTRANSFORMATION; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; LACTONES; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTORS, PURINERGIC P2; THIOPHENES; TICLOPIDINE;

EID: 75149174409     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. CAPRIE Steering Committee: A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996; 348: 1329-39
2. Mehta SR, Yusuf S, Peters RJ et al: Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet, 2001; 358: 527-33
3. Yusuf S, Zhao F, Mehta SR et al: Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med, 2001; 345: 494-502
4. Steinhubl SR, Berger PB, Mann JT III et al: CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA, 2002; 288: 2411-20
5. Chen ZM, Jiang LX, Chen YP et al: COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised, placebo-controlled trial. Lancet, 2005; 366: 1607-21
6. Sabatine MS, Cannon CP, Gibson CM et al: Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA, 2005; 294: 1224-32
7. Angiolillo DJ, Costa MA, Shoemaker SB et al: Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol, 2008; 101: 440-45
8. Angiolillo DJ, Bernardo E, Palazuelos J et al: Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost, 2008; 99: 161-68
9. Ozer O, Unal Aksu H, Hobikoglu G et al: Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes. Blood Coagul Fibrinolysis, 2009; (in press)
10. Guha S, Sardar P, Guha P et al: Dual antiplatelet drug resistance in patients with acute coronary syndrome. Indian Heart J, 2009; 61: 68-73
11. Kasotakis G, Pipinos II, Lynch TG: Aspirin resistance: Current evidence and clinical implications. J Vasc Surg, 2009; (in press)
12. Lars W, Varenhorst C, James S et al: Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirintreated patients with coronary artery disease. Eur Heart J, 2008; 29: 21-30
13. Farid NA, Smith RL, Gillespie TA et al: The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos, 2007; 35: 1096-104
14. Cattaneo M: ADP receptors antagonists. In: Platelet-Michelson AD (ed.), San Diego, CA: Academic Press, 2006: 1127-44
15. Wiviott SD, Braunwald E, McCabe CH et al: TRITON TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl Med, 2007; 357: 2001-15
16. Leger AJ, Covic L, Kuliopulos A: Protease-activated receptors in cardiovascular diseases. Circulation, 2006; 114: 1070-77
17. Chackalamannil S: Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem, 2006; 49: 5389-403
18. Chackalamannil S, Xia Y, Greenlee WJ et al: Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem, 2005; 48: 5884-87
19. Morrow DA, Scirica BM, Fox KA et al: TRA 2(o)P-TIMI 50 Investigators. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J, 2009; 158: 335-41
20. Cattaneo M: New P2Y12 blockers. J Thromb Haemost, 2009; 7: 262-65
21. van Giezen JJJ, Humphries RG: Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost, 2005; 31: 195-204
22. Huang J, Driscoll EM, Gonzales ML et al: Lucchesi. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J Pharmacol Exp Ther, 2000; 295: 492-99
23. Humphries RG, Tomlinson W, Ingall AH et al: Effect of the novel P2T receptor antagonist, AR-C69931MX, on thrombosis and hemostasis in the dog: comparison with GPIIb/IIIa antagonists. Haematologica, 2000; 85: 91-92
24. van Gestel MA, Heemskerk JW, Slaaf DW et al: In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol, 2003; 23: 518-23
25. Wang K, Zhou X, Zhou Z et al: Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol, 2003; 23: 357-62
26. Greenbaum AB, Grines CL, Bittl JA et al: Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J, 2006; 151: 689
27. Greenbaum AB, Ohman EM, Gibson CM et al: Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction STEP-AMI) angiographic trial. Am Heart J, 2007; 154: 702-9
28. Medicines Company: The Medicines Company discontinues phase 3 CHAMPION clinical trial program of cangrelor [press release]. May 13, 2009
29. Maintenance of Platelet Inhibition With Cangrelor (BRIDGE Study). http://clinicaltrials.gov/ct2/show/NCT00767507
30. Davi G, Patrono C: Platelet activation and atherothrombosis. N Engl J Med, 2007; 357: 2482-94
31. Hollopeter G, Jantzen HM, Vincent D et al: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature, 2001; 409: 145-47
32. Wihlborg AK, Wang L, Braun OO et al: ADP Receptor P2Y12 Is Expressed in Vascular Smooth Muscle Cells and Stimulates Contraction in Human Blood Vessels Thromb Vasc Biol, 2004; 24: 1810-15
33. Mamedova LK, Gao ZG, Jacobson KA: Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors. Biochem Pharmacol, 2006; 72: 1031
34. Daniel JL, Dangelmaier C, Jin J et al: Role of intracellular signalling events in ADP-induced platelet aggregation. Thromb Haemost, 1999; 82: 1322-26
35. Paul BZ, Jin J, Kunapuli SP: Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem, 1999; 274: 29108-14
36. Daniel JL, Dangelmaier C, Jin J et al: Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem, 1998; 273: 2024-29
37. Jin J, Daniel JL, Kunapuli SP: Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem, 1998; 273: 2030-34
38. Storey RF, Husted S, Harrington RA et al: Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol, 2007; 50: 1852-56
39. Husted S, Emanuelsson H, Heptinstall S et al: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J, 2006; 27: 1038-47
40. Tantry US, Bliden KP, Gurbel PA: AZD6140. Expert Opin Investig Drugs, 2007; 16: 225-29
41. Fontana P, Dupont A, Gandrille S et al: Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation, 2003; 108: 989-95
42. Hetherington SL, Singh RK, Lodwick D et al: Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol, 2005; 25: 252-57
43. Fontana P, Gaussem P, Aiach M et al: P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation, 2003; 108: 2971-73
44. Lars W: P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J, 2009; 30: 1964-77
45. James S, Akerblom A, Cannon CP et al: Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J, 2009; 157: 599-605
46. Wallentin L, Becker RC, Budaj A et al for the PLATO investigators: Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med, 2009; 361: 1045-57
47. Ramdeen N, Aronow WS, Chugh S, Asija A: Patients undergoing coronary angiography because of chest pain with hepatitis C virus seropositivity have a higher prevalence of obstructive coronary artery disease than a control group. Arch Med Sci, 2008; 4: 452-54
48. Angiolillo DJ, Capranzano P, Jacksonville FL: Pharmacology of emerging novel platelet inhibitors Am Heart J, 2008; 156: S10-15
49. van Giezen JJ, Berntsson P, Zachrisson H, Björkman JA: Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/ hemostasis. Thromb Res, 2009; 124(5): 565-71
50. Piestrzeniewicz K, Łuczak K, Maciejewski M, Goch JH: Impact of obesity and adipokines on cardiac structure and function in men with first myocardial infarction. Arch Med Sci, 2008; 4(2): 152-60
51. Storey RF, Melissa Thornton S et al: Ticagrelor yields consistent dosedependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets, 2009; 20(5): 341-48
52. Kumar A, Cannon CP: The current role of statins in acute coronary syndrome. Arch Med Sci, 2007; 3(4A): S115-25
53. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP: The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets, 2004; 15(2): 117-25
54. Husted S, Harrington RA, Cannon CP et al: Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. Int J Clin Pract, 2009; 63(4): 667-70
55. Lleva P, Aronow WS, Amin H et al: Prevalence of electrocardiographic abnormalities in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Arch Med Sci, 2008; 4(3): 259-62
56. Matsagas M, Jagroop IA, Geroulakos G, Mikhailidis DP: The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. Clin Appl Thromb Hemost, 2003; 9(2): 115-20
57. Banach M, Misztal M, Goch A et al: Predictors of atrial fibrillation in patients following isolated surgical revascularization. A metaanalysis of 9 studies with 28 786 patients. Arch Med Sci, 2007; 3(3): 229-39
58. Heusch P, Skyschally A, Leineweber K et al: The interaction of coronary microembolization and ischemic preconditioning: A third window of cardioprotection through TNF-alpha. Arch Med Sci, 2007; 3(2): 83-92
59. Smout JD, Mikhailidis DP, Shenton BK, Stansby G: Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost, 2004; 10(1): 9-18
60. Lai HM, Aronow WS, Rachdev A et al: Incidence of mortality in 1,040 patients with coronary heart disease or hypertensive heart disease with normal and abnormal left ventricular ejection fraction and with normal and abnormal QRS duration. Arch Med Sci, 2008; 4(2): 140-42